Free Trial
NASDAQ:LONA

Athira Pharma Q3 2025 Earnings Results & Report

Athira Pharma logo
$3.23 -0.24 (-6.92%)
As of 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Athira Pharma missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$1.68 versus the -$0.17 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Athira Pharma EPS Results

Actual EPS
-$1.68
Consensus EPS
-$0.17
Beat/Miss
Missed by -$1.51
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Q3 2025 Earnings FAQ

Athira Pharma (NASDAQ:LONA) reported earnings of -$1.68 per share for Q3 2025, missing the consensus estimate of -$0.17. The report was announced on Thursday, November 6, 2025.

Athira Pharma Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

View Athira Pharma Profile